전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,019 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

NG2 and DLL3 CAR-T cells (NG2 and DLL3 CAR-T cells)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleThe Affiliated Nanjing Drum Tow…Phase 2

NK cell perfusion group (NK cell perfusion group)

Abortion, Missed; Infertility Unexplained · Abortion, Missed

#AbortionMissed#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang Provincial People's Ho…Phase 2

NKG2D CAR-NK with PD-1 Antibody (NKG2D CAR-NK with PD-1 Antibody)

Anaplastic Throid Carcinoma · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleKAEDIPhase 1

NKG2D-based CAR T-cells (NKG2D-based CAR T-cells)

Hepatocellular Carcinoma; Glioblastoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleCelyad Oncology SAPhase 1

NKR-2 CAR-T Cells (NKR-2 CAR-T Cells)

AML, Adult; Myelodysplastic Syndromes · AML, Adult

#AMLAdult#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleNkarta, Inc.Phase 1

NKX101 - CAR NK cell therapy (NKX101 - CAR NK cell therapy)

Relapsed/Refractory AML; AML, Adult · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

NUC-3373 + bevacizumab (NUC-3373 + bevacizumab)

Colorectal Cancer; Colorectal Neoplasms · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#ColorectalNeoplasms+1
Trials 1Status Active
CGTLimited DatastaleNexcella Inc.Phase 2

NXC-201 CAR-T (NXC-201 CAR-T)

Light Chain (AL) Amyloidosis · Light Chain (AL) Amyloidosis

#LightChainALAmyloidosis#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleHadassah Medical OrganizationPhase 1

Naive HBI0101 CAR-T (Naive HBI0101 CAR-T)

Relapsed/Refractory Multiple Myeloma (MM) · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 2

Nanobody-Based CD19/CD22 Tandem Dual CAR-T (Nanobody-Based CD19/CD22 Tandem Dual CAR-T)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleAbGenomics B.V Taiwan BranchPhase 2

Neihulizumab Treatment (Neihulizumab Treatment)

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation · FRα

#FR#Antibody#Phase2#monoclonal-antibody#Steroid-refractoryaGvHDSubsequen+1
Trials 1Status Discontinued
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 2

Neoadjuvant ipilimumab (Neoadjuvant ipilimumab)

Renal Cell Carcinoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 3

nivolumab (Opdivo, Neoadjuvant ipilimumab + nivolumab)

Malignant Melanoma Stage III · Malignant Melanoma Stage III

#MalignantMelanomaStageIII#Antibody#Phase3#monoclonal-antibody#Bristol
Trials 1Status Recruiting
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 2

nivolumab (Opdivo, Neoadjuvant nivolumab)

Renal Cell Carcinoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 2

Neoadjuvant relatlimab (Neoadjuvant relatlimab)

Renal Cell Carcinoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleBiocadPhase 3

Netakimab (Netakimab)

Plaque Psoriasis · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Phase3#monoclonal-antibody#Biocad
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

New donor-derived CD7 CAR T-cell (New donor-derived CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Newly matched donor-derived CD5 CAR T-cells (Newly matched donor-derived CD5 CAR T-cells)

T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Newly matched donor-derived FL-33 CAR T therapy (Newly matched donor-derived FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
ADCLimited DatastaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+1
Trials 1Status Recruiting

39 / 51 pages

← PreviousNext →